Sociedad Americana de Hirudoterapia

Cost-Effectiveness of Vioptix versus Clinical Examination for Flap Monitoring of Autologous Free Tissue Breast Reconstruction.

Research article published in Plastic and reconstructive surgery (2021)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Observational studyEnsayos clínicosSchoenbrunner et al. · Plastic and reconstructive surgery, 2021

Abstract

BACKGROUND: Vioptix is a near-infrared spectroscopy tissue oximetry technology that allows for noninvasive monitoring of flap perfusion. Despite the reported benefits of Vioptix, the cost-effectiveness of this flap monitoring technology has not been compared to clinical examination alone. METHODS: A cost-effectiveness model, from the patient perspective, was constructed with two treatment arms: clinical examination versus clinical examination combined with Vioptix for flap monitoring after autologous, free flap breast reconstruction. Costs, utilities, and other model inputs were identified from the literature. One-way and probabilistic sensitivity analyses were performed. Gamma distributions were created for cost variables, and beta distributions were created for probability variables. An incremental cost-effectiveness ratio under $50,000 per quality-adjusted life-year (QALY) was considered cost-effective. All analyses were performed using TreeAge Pro (Williamstown, Mass.). RESULTS: Mean cost of autologous free tissue transfer breast reconstruction with clinical examination-based flap monitoring was found to be $37,561 with an effectiveness of 0.79, whereas the mean cost of clinical examination with Vioptix for flap monitoring was $39,361 with effectiveness of 0.82. This yielded an incremental cost-effectiveness ratio of $60,507 for clinical examination combined with Vioptix for flap monitoring. One-way sensitivity analysis revealed that clinical examination with Vioptix became cost-effective when the cost of Vioptix was less than $1487. Probabilistic sensitivity analysis found that clinical examination was cost-effective in 86.5 percent of cases. CONCLUSION: Although clinical examination combined with Vioptix is minimally more effective for flap monitoring after autologous, free flap breast reconstruction, clinical examination alone is the more cost-effective flap monitoring option.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsCost-Benefit AnalysisFemaleFree Tissue FlapsHumansMammaplastyModels, EconomicMonitoring, AmbulatoryOximetryPhysical ExaminationPostoperative ComplicationsQuality-Adjusted Life YearsSpectroscopy, Near-Infrared

Resumen

Vioptix is a near-infrared spectroscopy tissue oximetry technology that allows for noninvasive monitoring of flap perfusion. Despite the reported benefits of Vioptix, the cost-effectiveness of this flap monitoring technology has not been compared to clinical examination alone.

Por qué esto importa para la hirudoterapia

Este estudio de modelado de costo-efectividad comparó el examen clínico aislado frente al examen clínico combinado con la oximetría tisular por espectroscopia de infrarrojo cercano Vioptix para el monitoreo del colgajo tras reconstrucción mamaria con colgajo libre autólogo, encontrando que el examen clínico aislado fue más costo-efectivo (razón de costo-efectividad incremental de $60.507 para la rama con Vioptix). La relevancia para el ámbito de la ASH es indirecta: si bien la terapia con sanguijuelas puede emplearse para la congestión venosa del colgajo, este artículo no menciona sanguijuelas, hirudoterapia ni sustancias derivadas de la sanguijuela. El estudio se centra en la costo-efectividad de la tecnología de monitoreo postoperatorio desde la perspectiva del paciente. Ningún contenido del resumen conecta con la hirudoterapia más allá del contexto compartido de la cirugía de colgajo libre, donde las sanguijuelas ocasionalmente pueden servir como medida coadyuvante de rescate.

Citación

Cost-Effectiveness of Vioptix versus Clinical Examination for Flap Monitoring of Autologous Free Tissue Breast Reconstruction.

Schoenbrunner et al. · Plastic and reconstructive surgery, 2021

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.